Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06140537
Status:
RECRUITING
Last Update Posted:
2024-02-20
First Post:
2023-11-14
Brief Title:
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Study Overview
Official Title:
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Long-term allograft function in kidney transplant recipients KTRs remain suboptimal and graft failure causes significant morbidity and mortality with cardiovascular disease being the leading cause of death in KTRs and the most common cause of death with a functioning graft Sodium-glucose cotransporter 2 SGLT2 inhibitors safely lower cardiovascular and kidney disease risk in the non-transplant population yet data in KTRs are lacking This clinical trial seeks to establish the efficacy and safety of dapagliflozin a SGLT2 inhibitor for improving cardiovascular and kidney graft function in adult KTRs with type 2 diabetes and post-transplant diabetes and to leverage innovate translational methods to define the underlying mechanisms of action
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None